Last reviewed · How we verify
HX044
At a glance
| Generic name | HX044 |
|---|---|
| Sponsor | Hanx Biopharmaceuticals (Wuhan) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HX044 CI brief — competitive landscape report
- HX044 updates RSS · CI watch RSS
- Hanx Biopharmaceuticals (Wuhan) Co., Ltd. portfolio CI